Medical Physiology Department, Medical Research and Clinical Studies Institute, National Research Centre, El-Behouth St, Giza, Egypt.
Pathology Department, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov;396(11):3017-3031. doi: 10.1007/s00210-023-02507-4. Epub 2023 Jun 12.
The present work investigated the effect of α-lipoic acid (ALA) and caffeine-loaded chitosan nanoparticles (CAF-CS NPs) on obesity and its hepatic and renal complications in rats. Rats were divided into control, rat model of obesity induced by high fat diet (HFD), and obese rats treated with ALA and/or CAF-CS NPs. At the end of the experiment, the activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) and the levels of urea, creatinine, interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) were determined in the sera of animals. In addition, malondialdehyde (MDA), nitric oxide (NO), and reduced glutathione (GSH) were measured in hepatic and renal tissues. Renal Na, K-ATPase was assessed. The histopathological changes were examined in the hepatic and renal tissues. Obese rats showed a significant increase in AST, ALT, ALP, urea, and creatinine. This was associated with a significant increase in IL-1β, TNF-α, MDA, and NO. A significant decrease in hepatic and renal GSH and renal Na, K-ATPase activity was recorded in obese rats. Obese rats also showed histopathological alterations in hepatic and renal tissues. Treatment with ALA and/or CAF-CS NPs reduced the weight of obese rats and ameliorated almost all the hepatic and renal biochemical and histopathological changes induced in obese rats. In conclusion, the present findings indicate that ALA and/or CAF-CS NPs offered an effective therapy against obesity induced by HFD and its hepatic and renal complications. The therapeutic effect of ALA and CAF-CS NPs could be mediated through their antioxidant and anti-inflammatory properties.
本研究旨在探讨α-硫辛酸(ALA)和载咖啡因壳聚糖纳米粒(CAF-CS NPs)对肥胖及其肝肾功能并发症的影响。实验将大鼠分为对照组、高脂肪饮食(HFD)诱导肥胖组和肥胖大鼠 ALA 及/或 CAF-CS NPs 治疗组。实验结束时,检测各组大鼠血清中天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、碱性磷酸酶(ALP)、尿素、肌酐、白细胞介素-1β(IL-1β)和肿瘤坏死因子-α(TNF-α)的水平,并测定肝肾功能相关指标。同时,还检测了肝肾功能组织中的丙二醛(MDA)、一氧化氮(NO)和还原型谷胱甘肽(GSH)含量,评估了肾脏 Na,K-ATP 酶活性。观察肝肾功能组织的病理变化。结果显示,肥胖大鼠 AST、ALT、ALP、尿素和肌酐显著升高,同时,IL-1β、TNF-α、MDA 和 NO 也显著增加;肝肾功能组织中的 GSH 和肾 Na,K-ATP 酶活性明显降低,肝肾功能组织出现明显的病理改变。ALA 和/或 CAF-CS NPs 治疗可显著降低肥胖大鼠体重,减轻肥胖大鼠肝肾功能的生化和组织病理改变。综上所述,ALA 和/或 CAF-CS NPs 对 HFD 诱导的肥胖及其肝肾功能并发症具有治疗作用,其机制可能与抗氧化和抗炎作用有关。